CorMedix saw both firms lower their price targets, but both kept Outperform ratings. Those opposing signals leave the story without a clear change to the company's outlook.
The lower targets suggest the analysts see less share-price upside than before. Keeping Outperform ratings points the other way. The story gives no new sales or profit figures to settle those views.
Follow CorMedix Inc. (CRMD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CRMD